Skip to main content

Antidepressants for Depression in Patients with Dementia: A Review of the Literature

Buy Article:

$35.00 + tax (Refund Policy)

Objective: To evaluate the literature investigating the efficacy and safety of antidepressants for treating depression in individuals with dementia.

Data Sources: A literature search was conducted using MEDLINE, PUBMED, EMBASE, and Cochrane databases from inception to May 2013 for studies in English that evaluated the treatment of depression in patients with dementia. All relevant randomized controlled trials (RCTs) and meta-analyses were identified using the search terms “dementia” or “Alzheimer's disease,” and “depression” or “major depressive disorder.” Reference lists from retrieved articles and practice guidelines were also searched for relevant literature.

Study selection and data extraction: Only randomized, placebo-controlled trials and meta-analyses that compared an antidepressant with placebo for the treatment of depression in patients with dementia were included.

Data Synthesis: In this systematic review, 10 RCTs and 3 meta-analyses were identified that examined the efficacy and safety of antidepressants compared with placebo in treating depression in patients with dementia. The majority of the RCTs consisted of a small sample size, and the antidepressants studied were not routinely used in practice.

Conclusions: The evidence for antidepressants in the treatment of depression in patients with dementia is inconclusive. The accumulation of evidence suggests nonpharmacologic approaches and watchful waiting be attempted for the first 8 to 12 weeks in a patient who presents with both mild-to-moderate depression and dementia. In cases of severe depression, or depression not managed through nonpharmacologic means, a trial of an antidepressant may be initiated. However, further well-designed trials are needed to support these recommendations.

Keywords: AD = Alzheimer's disease; Alzheimer's disease; Antidepressants; CSDD = Cornell Scale for Depression in Dementia; DIADS-2 = Depression in Alzheimer's Disease Study-2; Dementia; Depression; HAM-D or HDRS = Hamilton Depression Rating Scale; HTA-SADD = Sertraline or Mirtazapine for Depression in Dementia; MADRS = Montgomery-Asberg Depression Rating Scale; MMSE = Mini-Mental State Examination; NINCDS-ADRDA = National Institute of Neurological and Communicative Diseases and Stroke - Azheimer's Disease and Related Disorders Association; RCT = Randomized controlled trial; SSRI = Selective serotonin reuptake inhibitor; mADCS-CGIC = Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change

Document Type: Research Article

Publication date: 01 April 2014

More about this publication?
  • The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Membership Information
  • Information for Advertisers
  • ">CLOCKSS Logo image
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content